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We previously reported that PGRN directly bound to TNF receptors (TNFR) in vitro and in chondro-
cytes (Tang, et al., Science, 2011). Here we report that PGRN also associated with TNFR in splenocytes,
and inhibited the binding of TNFa to immune cells. Proper folding of PGRN is essential for its bind-
ing to TNFR, as DTT treatment abolished its binding to TNFR. In contrast, the binding of PGRN to Sor-
tilin was enhanced by DTT. Protein interaction assays with mutants of the TNFR extracellular
domain demonstrated that CRD2 and CRD3 of TNFR are important for the interaction with PGRN,
similar to the binding to TNFa. Taken together, these ﬁndings provide the molecular basis underly-
ing PGRN/TNFR interaction and PGRN-mediated anti-inﬂammatory activity in various autoimmune
diseases and conditions.
Structured summary of protein interactions:
TNFR1 physically interacts with PGRN by two hybrid (View interaction)
TNFR2 physically interacts with PGRN by anti bait coimmunoprecipitation (View interaction)
TNF alpha binds to TNFR1 by surface plasmon resonance (View interaction)
TNFR1 binds to PGRN by pull down (View interaction)
TNFRSF1B and PGRN bind by surface plasmon resonance (View interaction)
TNFR1 binds to PGRN by solid phase assay (View interaction)
PGRN binds to Sortilin by solid phase assay (View interaction)
TNFR2 binds to PGRN by pull down (View interaction)
PGRN binds to TNFR2 by solid phase assay (1, 2)
PGRN binds to TNFR1 by surface plasmon resonance (View interaction)
TNF alpha binds to TNFR2 by surface plasmon resonance (View interaction)
TNFR2 physically interacts with PGRN by two hybrid (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction P–G–F–B–A–C–D–E, where A–G are full repeats and P is the half-Progranulin (PGRN) also known as granulin–epithelin precursor
(GEP) [1], proepithelin (PEPI) [2,3], acrogranin [4], and PC-cell
derived growth factor (PCDGF) [5], is a growth factor containing
seven and half cysteine-rich granulin domains in the order ofmotif [6]. Progranulin has multiple biological functions including
anti-inﬂammation and immune regulations [7]. PGRN acts as a
neurotrophic growth factor and stimulates neurite growth [8].
Mutations of the GRN gene are known to lead to the development
of frontotemporal lobar degeneration (FTLD) [9,10]. PGRN expres-
sion is elevated in activated microglia in many neurodegenerative
diseases including Creutzfeldt–Jakob disease, motor neuron
disease, multiple sclerosis and Alzheimer’s disease [9,11–14].
Growing evidences indicate that PGRN plays its neuroprotective
role through the modulation of neuroinﬂammation. PGRN-
deﬁcient mice have increased susceptibility to neuroinﬂammation
and neuron loss following toxin–induced injury [15], whereas mice
overexpressing PGRN exhibit a neuro-protective role by decreased
Fig. 1. PGRN interacts with TNFR in immune cells. (A) PGRN binds with TNFR2 in mouse splenocytes. Splenocytes were isolated from WT mouse and treated with PGRN
(100 ng/ml) and TNFa. (100 ng/ml) for 2 min and 10 min, respectively. The cells were lysed and membrane was further broken by brief sonication. The TNFR2 antibody was
used to precipitate TNFR2-associated proteins. The presence of PGRN and TNFR2 in the immunoprecipitated complex was examined using westernblotting with
corresponding antibodies. Rabbit IgG (RIgG) serves as a negative control and is indicated. (B) PGRN inhibits the binding of TNFa to cell surface in Jurkat cells. Jurkat cells, a T
cell leukemia cell line, were pretreated with various amounts of PGRN, as indicated, followed by incubation with biotinylated-TNFa. The binding of biotinylated-TNFa to cells
was examined with FACS.
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anti-inﬂammatory cytokine IL-10 in glial cells [16]. PGRN insufﬁ-
ciency in some autism patients results in reduced neurotropic sup-
port together with cumulative damage in association with
dysregulated inﬂammation [17]. Loss of function mutations in
the GRN gene are related to pro-inﬂammatory cytokine dysregula-
tion in FTLD patients [18]. In addition, mutations in GRN are also
associated with increased prevalence of speciﬁc and related auto-
immune diseases, including inﬂammatory arthritis [19,20].
PGRN binding receptors and signaling in mediating its anti-
inﬂammatory functions in neurons still remain elusive. Sortilin
has been shown to bind to PGRN via its last three amino acid res-
idues and mediate the endocytosis of PGRN in neurons [21,22].
However, PGRN was found to bind to Sort1 neurons [21], and to
regulate neuronal outgrowth independent of Sortilin [23]. PGRN-
mediated neurotrophic properties depend on the granulin E do-
main but do not require Sortilin binding [24], which indicates that
Sortilin is not the only neuronal PGRN receptor. Indeed, it was
found that PGRN bound directly to TNFR, and inhibited the
TNFa-mediated respiratory burst in neutrophils [25] and inﬂam-
matory diseases in mice [26], suggesting that PGRN/TNFR interac-
tions may contribute to PGRN-mediated neuroinﬂammation. The
importance of PGRN/TNFR interactions in regulating neuroinﬂam-
mation was further supported by several recent reports. For in-
stance, PGRN attenuated neuronal injury induced by cerebral
ischemia–reperfusion through the suppression of neutrophil
recruitment and inﬂammation [27]. PGRN was found to directly in-
hibit 125I-labeled TNF-a binding to the neutrophil surface, and inturn suppressed TNF-a induced neutrophil chemotaxis [27]. Addi-
tionally, PGRN treatment inhibited the TNFa-induced expression of
ICAM-1 in human brain microvascular endothelial cells [27]. Fur-
thermore, PGRN was also reported to suppress TNF-a-induced
expression of ICAM-1 and VCAM-1 in a dose-dependent manner
in human umbilical vein endothelial cells, and PGRN deﬁciency
promotes inﬂammation in the aortas of ApoE KO mice [28], indi-
cating that PGRN also plays a direct protective role in endothelial
cells and could be a promising pharmacological target molecule
in the treatment of cardiovascular diseases.
Although it has been established that three middle regions
(granulin F, A and C as well as linker regions involved) of PGRN,
which are separated by other non-binding regions, are required
for interacting with TNFR, the selection of appropriate reagents
and experimental procedures was found to be important for dem-
onstrating the sophisticated physical interaction of PGRN/TNFR.
Application of improperly folded PGRN, a highly cysteine-rich pro-
tein with extensive tertiary structure known to be critically linked
to function, and selection of inappropriate chips can lead to the
failure to demonstrate interactions between PGRN and TNFR, as re-
ﬂected in Chen’s paper [29]. In this study, we extend the previous
discovery by demonstrating that PGRN also interacts with TNFR in
immune system cells, examine the effects of PGRN folding on its
binding to receptors by comparing the binding of PGRN to TNFR
and Sortilin under various conditions, and provide information
for recapitulating the high-afﬁnity binding of PGRN to TNFR.
Importantly, we also dissect and identify the domains of TNFR
responsible for binding to PGRN.
Fig. 2. PGRN binds to TNFR on COOH1 chip, but not on COOHV chip in SensiQ surface plasmon resonance assay. (A) TNF binds to TNFR1 (red line) and TNFR2 (blue line) in
SensiQ COOHV chip. (B) PGRN fails to bind to both TNFR1 (red line) and TNFR2 (blue line) on COOHV chip. (C) TNFa binds to TNFR1 (red line) and TNFR2 (blue line) on COOH1
chip. (D) PGRN from adipogen binds to both TNFR1 (red line) and TNFR2 on COOH1 (blue line) chip.
Table 1
Summary of KD results from SPR.
KD values (nM) CM5 Chip
Biacore
COOHV Chip
SensiQ
COOH1 Chip
SensiQ
TNFR TNFR1 TNFR2 TNFR1 TNFR2 TNFR1 TNFR2
TNF a 2.3 1.0 1.2 0.37 3.4 0.7a
PGRN Adipogen
(HEK)
NB NB NB NB 1.55
(Repeated
x3)
0.2
(Repeated
x3)
NB = No binding detected or KD unable to be calculated due to weak signal.
a Values are for site 1 (high afﬁnity site) on a two-site binding model.
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2.1. Reagents
Human TNFa biotinylated ﬂuorokine Kit (Cat. No. NFTA0),
human Sortilin (Cat. No. 3154-ST), and human rTNFa (Cat. No.
210-TA) were purchased from R&D System. Human PGRN used in
Surface Plasmon Resonance was purchased from Adipogen, San
Diego, CA (Cat. No. AG-40A-0188). Recombinant human TNFR2
were purchased from Invitrogen (Cat. No. PHR3025). RIPA lysis
buffer, Protein A/G agarose beads, and antibodies against PGRN
(SC-28928) and TNFR2 (SC-7862) were ordered from Santa Cruz
Biotechnology. Jurkat cell, T cell leukemia cell line, was purchased
from ATCC.
2.2. Preparation of recombinant proteins
PGRN from our lab was puriﬁed from conditioned medium of
HEK-EBNA cells, which were stably transfected with human PGRN
with C-terminal His-tags as described previously [26]. Brieﬂy, cellswere cultured with serum-free medium for 3 days, and the med-
ium was then collected for PGRN puriﬁcation with the ProBond
Puriﬁcation System (Invitrogen, Carlsbad, CA). The protein purity
was determined with SDS–PAGE, and activity was measured with
a TNFa blocking assay.
Recombinant CRD2CRD3 domain of TNFR1 (R1/C2C3) and TNFR2
(R2/C2C3) were expressed as GST fusion proteins in corresponding
expression plasmids based on pGEX-3X vectors in Escherichia coli
DH5a (Invitrogen, Carlsbad, CA) under the induction of 0.25 mM
IPTG. Fusion proteins were afﬁnity-puriﬁed on glutathione-agarose
beads as described previously [26]. Factor Xa (New England Biolabs,
Ipswich, MA) was used to release R1/C2C3 or R2/C2C3, respectively,
from the fusion proteins. After digestion, the enzyme was removed
with the Xa removal resin (Qiagen Valencia, CA).
2.3. Co-Immunoprecipitation (Co-IP)
Mouse splenocytes were isolated, and treated with either PGRN
(100 ng/ml) or TNFa (100 ng/ml) for 2 min or 10 min. The cells were
lysed in modiﬁed RIPA lysis buffer containing 1-fold proteinase
inhibitors, PMSF, and sodium orthovanadate (from Santa Cruz Bio-
technology). Then cell lysates were brieﬂy sonicated to further dis-
rupt the membrane structure. 1 mg protein was used for
immunoprecipitation for each sample. 2 lg/ml of control IgG and
20 ll of protein A/G beads were added into the cell lysis mixture
to pre-clear the non-speciﬁc binding proteins. After centrifuging,
2 lg/ml of control IgG or TNFR2 antibodywas added to the superna-
tant respectively, and the mixture was incubated for 1 h at 4. Then
20 ll of protein A/G beadswere added and incubated overnight. The
beads were washed with lysis buffer for 6–8 times, and the protein
complex was separated by SDS–PAGE. The presence of PGRN and
TNFR2 was detected by probing with their respective antibodies.
Fig. 3. DTT treatment of PGRN abolishes its binding to TNFR, whereas enhances its binding to Sortilin. (A) Schematic diagram of PGRN structure and its domain/motifs
required for binding to TNFR and Sortilin. (B) DTT treatment disrupts the direct binding between PGRN and TNFR2. PGRN from our lab was pretreated with or without 10 mM
DTT, and various amounts of PGRN, as indicated, were coated on the plate. Binding to TNFR2 was measured as described above. (C) DTT treatment enhances the binding of
PGRN to Sortilin. Similar to B, same dosages of PGRN from our lab were pretreated with or without 10 mM DTT, the binding to Sortilin was measured.
J. Jian et al. / FEBS Letters 587 (2013) 3428–3436 34312.4. Surface plasmon resonance (SPR)
The Biacore experiments were conducted at the core facility of
Tufts University on CM5 chip. The SensiQ experiments were per-
formed by SensiQ Technologies, Inc., and both COOHV and COOH1
chips were used to measure the binding between TNFR with PGRN
[26].
2.5. SDS–PAGE and western blotting
Protein samples from immunoprecipitation or from protein
puriﬁcations were separated by SDS–PAGE. For protein puriﬁca-
tion, the gel was stained with Coomassie Blue for 30 min after elec-
trophoresis, and de-stained for several hours so the target band
could be visualized. For immunoprecipitation, the samples were
transferred to a nylon membrane after electrophoresis. The mem-
brane was probed with the primary antibody overnight at 4 C, and
with the secondary antibody for 2 h at room temperature. The
bands were developed on the ﬁlm using ECL Prime Western
Blotting Detection Reagent (Amersham Pittsburgh, PA).
2.6. TNFa blocking assay
This experiment mainly followed the protocol of the manufac-
turer (Cat. No. NFTA0 R&D System). Jurkat cells were suspended
in 0.4% BSA PBS buffer. The cells were pre-treated with BSA or
PGRN (1, 5, 10 lg) for 15 min. Biotinylated TNFa was added for
1 h, then FITC-labeled streptavidin was added. In another tube,
anti-TNFa antibody was added as a positive control for inhibition
of TNFa binding. The staining was measured by ﬂow cytometry
at the NYU core facility.
2.7. Solid phase binding assay
Various doses of PGRN or BSA were coated to an ELISA plate
overnight. After blocking, biotin-labeled TNFR was added and the
plate was incubated for 2 h. Finally streptavidin-conjugated with
horseradish peroxidase (HRP) was added and the binding between
PGRN and TNFR2 was detected by incubation of the substrate of
HRP. In other experiments plates were coated overnight withdifferent doses of R1/C2C3 or R2/C2C3. Then biotin-labeled PGRN
was added followed by HRP-conjugated streptavidin in the plate.
The interactions between PGRN and R1/C2C3, or R2/C2C3 were de-
tected as described above.
In another experiment, plates were coated overnight with vari-
ous doses of PGRN in PBS buffer in the presence or absence of
10 mM DTT. After blocking, biotin-labeled TNFR2 or Sortilin was
added to each well. The bound protein from the liquid phase was
then detected by HRP-conjugated streptavidin.
2.8. The yeast two-hybrid system
Full-length pDB-TNFR1 and pDB-TNFR2 plasmids were used as
templates to amplify fragments of the cysteine-rich domains
(CRD). Every CRD and combination of CRDs of TNFR1 was produced
and ligated to a pDB-leu vector with SalI and NotI. CRDs of TNFR2
went through the same procedure except that they were digested
with NcoI and NotI. PGRN gene was cloned into the pPC86 vector.
The same strategywas used as the discovery of PGRN–TNFR interac-
tion, referred to as a modiﬁed yeast-two-hybrid (Y2H) system in
previous reports [26]. Positive interactions between the bait and
prey protein couples were displayed as blue dots on the membrane.
2.9. GST pull-down assay
GST-fusion proteins, R1/C2C3 and R2/C2C3, were conjugated to
Glutathione-Sepharose beads, which were further incubated with
puriﬁed PGRN at 4 C overnight. GST-conjugated beads were incu-
bated with the same amount of PGRN as a control. Bound proteins
were resolved by 10% SDS–PAGE and detected by western blotting
with anti-PGRN antibody.
3. Results
3.1. PGRN binds to TNFR2 in splenocytes and inhibits the binding
of TNFa to immune cells
Our previous study found that PGRN bound to TNFR in chondro-
cytes and that the administration of PGRN could prevent TNFa-
induced inﬂammatory arthritis [26,30]. Attempting to apply our
Fig. 4. CRD2 and CRD3 domains of TNFR are important for binding to PGRN. (A) PGRN binds with CRD2 and CRD3 domains of TNFR1 in yeast two-hybrid system. Different
combinations of TNFR1 CRD domains were generated on the left, and their binding to PGRN was detected by X-gal activity as shown on the right. (B) PGRN binds to CRD2 and
CRD3 domains of TNFR2 in yeast two-hybrid system. Similar truncations of TNFR2 CRD domains were indicated on the left, and their binding to PGRN was detected by X-gal
activity as shown on the right.
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cipitation to study the interaction between PGRN and TNFR2 in
splenocytes. Splenocytes were isolated from mice and treated with
PGRN or TNFa for 2 and 10 min. The cell lysates were used in the
immunoprecipitation with anti-TNFR2 antibody. As shown in
Fig. 1A, PGRN and TNFR2 are detectable in the immunoprecipitated
complexes from splenocytes, and the signaling was enhanced by
PGRN and TNFa treatment. In addition, PGRN inhibited the binding
of TNFa to Jurkat cells in a dose-dependent manner (Fig. 1B). These
results show that PGRN binds to TNFR and prevents TNFa binding
to membrane receptors not only in chondrocytes [26], but also in
the immune system [27].
3.2. Selection of appropriate chips in surface plasmon resonance is
important for demonstrating the binding of PGRN to TNFR
We previously reported that PGRN from our lab binds to TNFR1
and TNFR2 with the KD of 1.8 and 1.5 nM, respectively [26]. This
ﬁnding was conﬁrmed by Atreaon Inc. through independentlycontracted services (Fig. 2; Table 1). As shown in Fig. 2A and C,
TNFa binds to TNFR on COOH1 and COOHV chips in SensiQ meth-
ods. When tested on the COOH1 chip, the same chip used in our
previous study [26], PGRN from Adipogen shows high binding
afﬁnity to both TNFR1 and TNFR2 (Fig. 2D). Consistent with our
previous study [26], PGRN shows selectively higher binding afﬁnity
to TNFR2 than to TNFR1. However, when switched to COOHV chip,
PGRN fails to bind to TFNR (Fig. 2B). These data were repeated in
three individual experiments. Furthermore PGRN fails to bind to
TNFR1 and TNFR2 in CM5 chips in Biacore, which is the same chip
used in Chen’s study [29]. As summarized in Table 1, the successful
demonstration of the binding of PGRN to TNFR1 and TNFR2 in sur-
face plasmon resonance is highly dependent upon the chips used.
3.3. Proper folding of PGRN is critical for its binding to TNFR, but not to
Sortilin
The Grn F, A, and C domains are required for PGRN to bind to
TNFR [26], whereas only the C-terminus of Grn E, particularly the
Fig. 5. Direct Binding of PGRN to CRD2CRD3 of TNFR in vitro. (A) GST pull-down
assay. GST (serves as a negative control) or GST fused CRD2CRD3 of TNFR1 (R1/
C2C3) and TNFR2 (R2/C2C3) fusion protein immobilized on glutathione-Sepharose
beads were incubated with recombinant PGRN. PGRN trapped was examined by
immunoblotting with anti-PGRN antibodies (left panel); Coomassie blue staining
shows that the comparable fusion proteins were used in this experiment (right
panel). GST (lane 1) and GST fused CRD2CRD3 of TNFR1 (lane 2) and CRD2CRD3 of
TNFR2 (lane 3) are indicated with arrows as GST and C2C3, respectively. (B)
Recombinant CRD2CRD3 of TNFR1 (TNFR1/C2C3) binds to PGRN. Puriﬁed R1/C2C3
protein was obtained after cleavage of GST moiety, and was used to bind to PGRN in
a solid phase assay as described above. (C) Recombinant CRD2CRD3 of TNFR2
(TNFR2/C2C3) binds to PGRN. Similar to R1/C2C3, R2/C2C3 were also obtained after
removal of GST moiety, and further used in a solid phase binding assay.
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[22]. We hypothesize that the binding of PGRN to TNFR requires
proper folding of PGRN so that all three regions required for TNFR
binding can form a trimer-like structure and are accessible to
TNFR. To test this hypothesis, PGRN was pretreated with 10 mM
DTT, which is known to disturb the formation of disulﬁde bonds
in PGRN and in turn affects its folding, and then the binding of
PGRN to TNFR2 and Sortilin were measured using solid phase bind-
ing. DTT treatment completely abolished the binding of PGRN to
TNFR2 (Fig. 3A). In marked contrast, the binding of PGRN to Sortilin
was signiﬁcantly enhanced by DTT treatment (Fig. 3B). This result
clearly shows that proper folding and conformation of PGRN are re-
quired for binding to TNFR, but not to Sortilin. Thus, use of Sortilin
binding activity to validate the biological and TNFR-binding activ-
ities of PGRN, as in Chen’s paper [29], is inappropriate.3.4. CRD2 and CRD3 of TNFR are responsible for the binding of PGRN
We reported that three middle regions (granulin F, A and C as
well as linker regions involved) of PGRN are required for interac-
tion with TNFR [26]. However it was still unclear which domain(s)
of TNFR are responsible for binding to PGRN. The extracellular do-
mains of both TNFR1 and TNFR2 contain the similar structure of
four cysteine-rich domains (CRD), including the well-organized
CRD1, CRD2, and CRD3 domains and the less regular CRD4 domain,
which is head-to-tail ligated with little overlap [31]. To identify the
domains of TNFR important for PGRN binding, we generated vari-
ous combinations of CRD1–4 domains of both TNFR1 and TNFR2.
The interactions between PGRN and CRD1–4 domains of TNFR1
and TNFR2 were tested in yeast two hybrid systems as reported
previously [26,30]. As expected, PGRN showed clear binding afﬁn-
ity for CRD1–4 of TNFR1 extracellular domain. Both CRD1–4 and
CRD1–3 of TNFR1 showed strong binding to PGRN, and the binding
was completely lost after further deletion of the CRD3 domain of
TNFR1, indicating that the CRD3 domain of TNFR1 is essential for
binding to PGRN. Single CRD3 domain only exhibited weak bind-
ing, and CRD2 and CRD3 domain (C2C3) displayed comparable
binding with PGRN as the full-length extracellular domain of
TNFR1 (Fig. 4A). This result revealed that in the interaction be-
tween PGRN and TNFR1, the CRD3 domain of TNFR1 was the deter-
minant for the binding, whereas CRD2 played an important role in
enhancing this binding to a substantial degree.
Similar to TNFR1, the CRD3 domain of TNFR2 is also essential
for binding to PGRN. However, unlike in TNFR1, CRD3 alone of
TNFR2 showed strong binding to PGRN, and the CRD1-CRD2 also
displayed weaker binding to PGRN (Fig. 4B). This discrepancy
may explain why PGRN shows higher binding afﬁnity to TNFR2
than to TNFR1 [26].
CRD2 and CRD3 of TNFR are known to be required for binding
TNFa [32,33] , and yeast two hybrid (Y2H) system also demon-
strated that they are important for binding PGRN. To further verify
the binding discovered in Y2H, the GST-pull down assay was per-
formed. As shown in Fig. 5A, PGRN was pulled-down by both
GST-fused CRD2CRD3 domain of both TNFR1 and TNFR2, but not
by GST control. To eliminate the potential effect by GST, GST moi-
ety from GST-R1C2C3 and GST-R2/C2C3 was cleaved by Xa factor
and the untagged CRD2 CRD3 of TNFR1 (R1/C2/D3) and TNFR2
(R2/C2C3) were puriﬁed. The direct binding to PGRNwas measured
by solid phase assay. As shown in Figs. 5B and C, both R1/C2C3 and
R2/C2C3 proteins showed dose-dependent binding activity to
PGRN.
4. Discussion
PGRN-mediated inhibition of TNFa activity has been well estab-
lished [25,34,35]. For instance, incubation of human neutrophils
with PGRN diminishes the production of reactive oxygen species
(i.e., the oxidative burst), which is triggered when cells are exposed
to TNFa [25]. Moreover, this effect of PGRN is enhanced by the
presence of a serine protease inhibitor that protects PGRN from
degradation. We reported previously that PGRN bound directly to
TNFR and inhibited the binding of TNFa to TNFR [26], which is con-
sistent with these earlier ﬁndings and provides a molecular basis
underlying PGRN-mediated anti-TNFa activity. Recent experimen-
tal and epidemiological evidence from several laboratories also
supports the importance of PGRN/TNFR interaction in inﬂamma-
tory diseases and conditions. It was found that PGRN protected
lung inﬂammation in vivo and the PGRN-mediated protective
effect depended on PGRN/TNFR2 interaction [34]. Enhanced
neuroinﬂammation was observed in PGRN-deﬁcient mice [15],
whereas mice overexpressing PGRN exhibit neuroprotective role
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ported to ameliorate ischemia–reperfusion induced neuronal in-
jury, and this ameliorative effect resulted from the suppression
of neutrophil recruitment and inﬂammation by PGRN [27], since
PGRN was found to directly inhibit the binding of TNF-a to the
neutrophil surface, and in turn, to suppress TNF-a induced neutro-
phil chemotaxis. Additionally, PGRN also plays a protective role in
atherosclerosis, as PGRN suppresses TNFa-induced expression of
ICAM-1 and VCAM-1 in umbilical vein endothelial cells, and PGRN
deﬁciency exacerbates inﬂammation and atherosclerosis[28]. Fur-
thermore, mutations in GRN were associated with an increased
prevalence of speciﬁc and related autoimmune diseases, including
inﬂammatory arthritis [19,20].
We have shown that PGRN associated with TNFR in chondro-
cytes and was therapeutic in inﬂammatory arthritis [26]. In the
present study we present further evidence in a Co-Immunoprecip-
itation (Co-IP) assay demonstrating that PGRN interacts with TNFR
in immune cells as well. This ﬁnding provides the molecular and
cellular mechanism by which PGRN mediates anti-inﬂammation
in various kinds of autoimmune diseases, including rheumatoid
arthritis. Although Co-IP assay is known to be an important tool
for detecting the in vivo interactions of endogenous proteins, the
procedure is technically challenging when handling low abun-
dance membrane proteins. The key is the selection of an appropri-
ate detergent to efﬁciently release the proteins from the lipid
bilayer membrane without disturbing the protein complexes. Any
inappropriate concentrations/procedures may lead to negative re-
sults. The inability to detect Co-IP of endogenous TNFR and PGRN
in neuroblastoma was reported by Chen et al. [29], but it is unclear
whether the TNFR complexes were extracted from the membrane
successfully, as data validating the experimental approach was
not shown, for instance, whether TNFR antibodies could precipitate
the known components of TNFR complexes. Additionally, the
abundance of the proteins of interest in the membrane is also
important for successfully demonstrating the interactions. As
shown in Fig. 1A, PGRN precipitated by anti-TNFR2 antibody was
clearly enhanced when splenocytes were treated with either PGRN
or TNFa, which are known to upregulate the expression of TNFR2
[36].
PGRN is a highly cysteine-rich glycoprotein, and contains
numerous internal disulﬁde bonds, which are critical for maintain-
ing the proper folding and conformation of this protein [37]. Tol-
katchev [38] showed that of the 7 ½ individual granulin domains
that comprise PGRN, only granulins A, F and C contain well-deﬁned
three-dimensional structures consisting of a complex laddering of
disulﬁde bonds. Importantly, our work also demonstrated that it is
these same three granulin units – F, A and C, that are required for
binding TNFR [26]. Proper folding of PGRN is critical for its binding
to TNFR, as three middle granulin domains F, A, and C of PGRN are
separated by other non-binding regions, and are required for inter-
acting with TNFR [26]. Indeed, DTT treatment, which is known to
disturb the formation of disulﬁde bonds and in turn affecting pro-
tein folding, completely abolished binding of PGRN to TNFR (Fig. 3).
In marked contrast, the binding of PGRN to Sortilin was actually
enhanced by DTT treatment. This ﬁnding is probably due to the fact
that the very last C-terminal three amino acids (QLL) of PGRN,
known to be required for Sortilin binding [22], are exposed in the
unfolded PGRN and become more easily accessible to Sortilin.
Thus, because the conformational requirements for the binding of
PGRN to Sortilin are substantially less stringent than those for
binding to TNFR, demonstration of binding to Sortilin is an inap-
propriate litmus test for documenting that the recombinant PGRN
is properly folded and thereby capable of interacting with TNFR.
Posttranslational modiﬁcations of PGRN, including glycosyla-
tion, could be another important factor affecting its binding to
TNFR. PGRN is composed of 593 amino acids but displays anapparent molecular weight of approximately 90 kDa, which indi-
cates that PGRN contains post-translational modiﬁcations, includ-
ing glycosylation [39]. PGRN is known to possess multiple N-
glycosylation sites, and treatment of N-glycosidase F decreased
the molecular weight of PGRN from 88 kDa to 68 kDa [5]. Recom-
binant PGRN produced from a HEK-EBAN stable line and PGRN
purchased from R&D Systems exhibited a slight difference in gel
mobility assay (data not shown), indicating that they may not con-
tain the similar modiﬁcations and in turn conformation and TNFR
binding activity accordingly. We reported earlier that some
batches of PGRN purchased from R&D Systems did not show clear
binding afﬁnity to TNFR in the solid phase binding assay [7]. Vari-
ations in TNFR binding and biological activities among puriﬁcation
batches of PGRNs from various sources are quite similar to the dis-
crepancy between different puriﬁcations of perlecan, a PGRN-bind-
ing glycoprotein [40]. Perlecans puriﬁed from different cell types or
the same cell type with different expression systems have been
shown to have the potential for signiﬁcant variation in glycosyla-
tion and function, and can vary dramatically in FGF receptor-based
assays or in growth factor binding assays [41–43].
Surface plasmon resonance (SPR) assay is a widely used ap-
proach to demonstrate the direct interactions among macromole-
cules [44]. The type of equipment and the selection of the chip
are critical in general [45] as well as in the stoichiometry of TNF
binding to TNFR [46], and also appear to be important for detecting
the binding of PGRN to TNFR. We have reported previously the
binding of PGRN from our lab to TNFR using the COOH1 chip, a pla-
nar PEG-based chip, at SensiQ [26]; this ﬁnding has now been re-
peated with PGRN from Adipogen. However, no binding was
observed using the COOHV chip, a 3D Dextran chip. In addition,
CM5 chip in a Biacore (used in Chen’s paper [29]) did not detect
the binding of PGRN to TNFR, either. As described in the letter-
to-editor concerning Chen’s paper [29] (http://www.jneuro-
sci.org/content/33/21/9202/reply#jneuro_el_111445), the demon-
stration of delicate interactions of PGRN/TNFR with SPR is highly
dependent upon the type of chip used as well as the source of
the recombinant PGRNs, and changes of chips or sources of recom-
binant proteins, etc., may lead to negative results. Matrix coated on
the chips, such as Dextran on COOHV chip, appears to interfere
with binding of PGRN to TNFR1 and TNFR2, but does not affect
the binding of TNFa to TNFR (Fig. 2). Failure of the CM5 and COO-
HV chips may be also related to their high immobilization capacity,
whereas low capacity is preferable for kinetic experiments (Bia-
core, Gedig, and Van der Merwe).
The yeast two-hybrid system, followed by conﬁrmation with
GST pull-down and solid phase binding assays, revealed that PGRN
interacted with the CRD2 and CRD3 of TNFR. The interaction be-
tween TNFa and TNFR has been reported to be via these same CRDs
[32,33]. CRD3 was the essential domain for the binding to PGRN,
whereas CRD2 enhanced it to a large scale (Figs. 4 and 5). This ﬁnd-
ing is in accordance with the report that CRD3 is ‘‘an ideal candi-
date for binding speciﬁcity control’’ and serves as the
determinant, whereas CRD2 plays a modulation function during
interactions [47]. Collectively, our results establish that CRD2 and
CRD3 extracellular domains of TNFR are important for mediating
the interactions between TNFR and PGRN. Dissection and identiﬁ-
cation of domains of TNFR responsible for PGRN binding provide
the molecular basis underlying the PGRN/TNFR interaction and
the PGRN-mediated anti-TNF activity in various kinds of diseases
and conditions.
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